InMed Pharmaceuticals (INM) Cost of Revenue (2021 - 2025)

InMed Pharmaceuticals has reported Cost of Revenue for 5 years, with the latest figure at $635994.0 in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue fell 2.28% year-over-year to $635994.0; the trailing twelve-month figure through Dec 2025 stood at $3.2 million (up 1.43% YoY), and the FY2025 full-year result was $3.2 million, down 7.46% from the prior year.
• Cost of Revenue for Q4 2025 stood at $635994.0, down from $716962.0 in the prior quarter.
• The five-year high for Cost of Revenue was $1.3 million in Q2 2023, with the low at $127308.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $668484.4 across 5 years, with a median of $728056.0 in 2025.
• Annual changes were most pronounced in 2023 — Cost of Revenue surged 560.93% — and 2024, when it sank 37.99%.
• InMed Pharmaceuticals' Cost of Revenue stood at $153537.0 in 2021, then soared by 120.55% to $338620.0 in 2022, then soared by 170.53% to $916058.0 in 2023, then dropped by 28.96% to $650813.0 in 2024, then decreased by 2.28% to $635994.0 in 2025.
• The last three Cost of Revenue figures came in at $635994.0 (Q4 2025), $716962.0 (Q3 2025), and $728056.0 (Q2 2025), per Business Quant data.